Literature DB >> 21613474

Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.

Elisa A Waxman1, Benoit I Giasson.   

Abstract

Intracytoplasmic proteinaceous inclusions, primarily composed of tau or α-synuclein (α-syn), are predominant pathological features of Alzheimer's disease (AD) and Parkinson's disease (PD), respectively. However, the coexistence of these pathological aggregates is identified in many neurodegenerative disorders, including spectrum disorders of AD and PD. Whereas α-syn can spontaneously polymerize into amyloidogenic fibrils, in vitro, tau polymerization requires an inducing agent. The current study presents a human-derived cellular model, in which recombinant, preformed α-syn fibrils cross-seed intracellular tau to promote the formation of neurofibrillary tangle-like aggregates. These aggregates were hyperphosphorylated, Triton insoluble, and thioflavin-S positive, either comingling with endogenously expressed α-syn aggregates or induced by only exogenously applied recombinant α-syn fibrils. Furthermore, filamentous, amyloidogenic tau took over the cellular soma, displacing the nucleus and isolating or displacing organelles, likely preventing cellular function. Although a significant proportion of wild-type tau formed these cellular inclusions, the P301L mutation in tau increased aggregation propensity resulting from α-syn seeds to over 50% of total tau protein. The role of phosphorylation on the development of these tau aggregates was investigated by coexpressing glycogen synthase kinase 3 β or microtubule-associated protein/microtubule affinity-regulating kinase 2. Expression of either kinase inhibited the formation of α-syn-induced tau aggregates. Analyses of phosphorylation sites suggest that multiple complex factors may be associated with this effect and that Triton-soluble versus Triton-insoluble tau may be independently targeted by kinases. The current work not only provides an exceptional cellular model of tau pathology, but also examines α-syn-induced tau inclusion formation and provides novel insights into hyperphosphorylation observed in disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613474      PMCID: PMC3122484          DOI: 10.1523/JNEUROSCI.0297-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  83 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Chemical pathology of neurofibrils. Neurofibrillary tangles of Alzheimer's presenile-senile dementia.

Authors:  K Iqbal; H M Wisniewski; I Grundke-Iqbal; J K Korthals; R D Terry
Journal:  J Histochem Cytochem       Date:  1975-07       Impact factor: 2.479

3.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

Authors:  He-Jin Lee; Ji-Eun Suk; Eun-Jin Bae; Jung-Ho Lee; Seung R Paik; Seung-Jae Lee
Journal:  Int J Biochem Cell Biol       Date:  2008-01-20       Impact factor: 5.085

4.  Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes.

Authors:  Philipp J Kahle; Manuela Neumann; Laurence Ozmen; Veronika Muller; Helmut Jacobsen; Will Spooren; Babette Fuss; Barbara Mallon; Wendy B Macklin; Hideo Fujiwara; Masato Hasegawa; Takeshi Iwatsubo; Hans A Kretzschmar; Christian Haass
Journal:  EMBO Rep       Date:  2002-05-24       Impact factor: 8.807

5.  Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.

Authors:  Karin Boekhoorn; Dick Terwel; Barbara Biemans; Peter Borghgraef; Olof Wiegert; Ger J A Ramakers; Koos de Vos; Harm Krugers; Takami Tomiyama; Hiroshi Mori; Marian Joels; Fred van Leuven; Paul J Lucassen
Journal:  J Neurosci       Date:  2006-03-29       Impact factor: 6.167

Review 6.  The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease.

Authors:  T Crowther; M Goedert; C M Wischik
Journal:  Ann Med       Date:  1989       Impact factor: 4.709

7.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

8.  Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos.

Authors:  X He; J P Saint-Jeannet; J R Woodgett; H E Varmus; I B Dawid
Journal:  Nature       Date:  1995-04-13       Impact factor: 49.962

9.  Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.

Authors:  Wen-Lang Lin; Jada Lewis; Shu-Hui Yen; Michael Hutton; Dennis W Dickson
Journal:  J Neurocytol       Date:  2003-11

Review 10.  A century of Alzheimer's disease.

Authors:  Michel Goedert; Maria Grazia Spillantini
Journal:  Science       Date:  2006-11-03       Impact factor: 47.728

View more
  94 in total

1.  Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.

Authors:  Amanda N Sacino; Mieu Brooks; Michael A Thomas; Alex B McKinney; Nicholas H McGarvey; Nicola J Rutherford; Carolina Ceballos-Diaz; Janice Robertson; Todd E Golde; Benoit I Giasson
Journal:  Acta Neuropathol       Date:  2014-05       Impact factor: 17.088

2.  Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Authors:  Zachary A Sorrentino; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Kevin H Strang; Jason Caldwell; Benoit I Giasson
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

Review 3.  Dynamic droplets: the role of cytoplasmic inclusions in stress, function, and disease.

Authors:  Triana Amen; Daniel Kaganovich
Journal:  Cell Mol Life Sci       Date:  2014-10-05       Impact factor: 9.261

Review 4.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

5.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

6.  Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular α-synuclein in oligodendrocytes.

Authors:  Katharina Pukass; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2013-11-12       Impact factor: 3.444

7.  The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation.

Authors:  Georges Mairet-Coello; Julien Courchet; Simon Pieraut; Virginie Courchet; Anton Maximov; Franck Polleux
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

Review 8.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

Review 9.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  Untangling a role for tau in synucleinopathies.

Authors:  Marion Delenclos; Simon Moussaud; Pamela J McLean
Journal:  Biol Psychiatry       Date:  2015-11-15       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.